Skip to main content

Becton, Dickinson and Company (BDX) Stock Analysis

SellModerate Confidence

Healthcare · Medical Instruments & Supplies

Sell if holding. Momentum 2.4/10 is below the 5.0 floor at $143.44 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Weak growth.

Becton Dickinson is a global medical technology company with three segments—BD Medical (IV systems, infusion pumps, pharmaceutical packaging), BD Life Sciences (diagnostics, biosciences), and BD Interventional (surgery, vascular, urology)—sold in over 100 countries to hospitals,... Read more

$143.44+12.0% A.UpsideScore 5.3/10#16 of 25 Medical Instruments & Supplies
QualityF-score8 / 9FCF yield11.55%
IncomeYield2.95%(5y avg 1.64%)Payout72.95%
Stop $137.75Target $159.46(analyst − 13%)A.R:R 1.8:1
Analyst target$183.29+27.8%14 analysts
$159.46our TP
$143.44price
$183.29mean
$225

Sell if holding. Momentum 2.4/10 is below the 5.0 floor at $143.44 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.

Recent Developments — Becton, Dickinson and Company

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (4/4)
Attractive valuation
Risks
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
Weak growth
Negative momentum

Key Metrics

P/E (TTM)24.8
P/E (Fwd)10.6
Mkt Cap$39.2B
EV/EBITDA9.0
Profit Mgn5.1%
ROE6.7%
Rev Growth5.2%
Beta0.28
Dividend2.95%
Rating analysts21

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C1.85bearish
IV128%elevated
Max Pain$340+137.0% vs spot

Material Events(8-K, last 90d)

  • 2026-04-09Item 5.02MEDIUM
    Richard E. Byrd, EVP and President of the Interventional segment, departed effective April 6, 2026. No successor named in available filing text; no reason for departure cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
2.2
Volume
4.2
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+1.4%/30d) — pullback in uptrend, not confirmed weakness

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
3.8
Low model confidence on this dimension (33%).
GatesMomentum 2.4<4.5A.R:R 1.8 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
42 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $142.01Resistance $159.61

Price Targets

$138
$159
A.Upside+11.2%
A.R:R1.8:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 2.4/10 — below 4.5 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is BDX stock a buy right now?

Sell if holding. Momentum 2.4/10 is below the 5.0 floor at $143.44 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $137.75. Score 5.3/10, moderate confidence.

What is the BDX stock price target?

Take-profit target: $159.46 (+12.0% upside). Prior stop was $137.75. Stop-loss: $137.75.

What are the risks of investing in BDX?

V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3); Weak growth; Negative momentum.

Is BDX overvalued or undervalued?

Becton, Dickinson and Company trades at a P/E of 24.8 (forward 10.6). TrendMatrix value score: 7.1/10. Verdict: Sell.

What do analysts say about BDX?

21 analysts cover BDX with a consensus score of 3.7/5. Average price target: $183.

What does Becton, Dickinson and Company do?Becton Dickinson is a global medical technology company with three segments—BD Medical (IV systems, infusion pumps,...

Becton Dickinson is a global medical technology company with three segments—BD Medical (IV systems, infusion pumps, pharmaceutical packaging), BD Life Sciences (diagnostics, biosciences), and BD Interventional (surgery, vascular, urology)—sold in over 100 countries to hospitals, clinics, and laboratories. A pending Reverse Morris Trust transaction will spin off the Biosciences and Diagnostic Solutions businesses combined with Waters Corporation, with BD receiving ~$4 billion pre-close. The company operates under an FDA consent decree affecting its Alaris infusion pump product line.

Related stocks: TFX (Teleflex Incorporated) · RMD (ResMed Inc.) · WST (West Pharmaceutical Services, I) · BLCO (Bausch + Lomb Corporation) · COO (The Cooper Companies, Inc.)